Evidence map›Paper›PMID 39044184›Full record

ArticleJournal of translational medicine2024

Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer.

Chiara Papulino, Ugo Chianese, Ahmad Ali, Gregorio Favale, Concetta Tuccillo, Fortunato Ciardiello, Annabella Di Mauro, Chiara Mignogna, Gerardo Ferrara, Alfredo Budillon and 9 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chiara Papulino *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Ugo Chianese *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Ahmad AliDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Gregorio FavaleDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Concetta TuccilloDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Fortunato CiardielloDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Annabella Di MauroPathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131, Naples, Italy.
Chiara MignognaPathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131, Naples, Italy.
Gerardo FerraraPathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131, Naples, Italy.
Alfredo BudillonScientific Directorate, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131, Naples, Italy.
Wouter Leonard MegchelenbrinkDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Nunzio Del GaudioDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Mariarosaria ConteDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Fabrizio MerciaiDepartment of Pharmacy (DIFARMA), University of Salerno, 84084, Salerno, Italy.
Pietro CampigliaDepartment of Pharmacy (DIFARMA), University of Salerno, 84084, Salerno, Italy.
Lucia AltucciDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.
Vincenzo Carafa *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy. vincenzo.carafa@unicampania.it.
Eduardo Sommella *Department of Pharmacy (DIFARMA), University of Salerno, 84084, Salerno, Italy. esommella@unisa.it.
Rosaria Benedetti *Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy. rosaria.benedetti@unicampania.it.

Funding

Ministero della Salute PNRR-MAD-2022-12376723Ministero della Salute Ricerca Corrente Funds to Istituto Nazionale Tumori G. Pascale.Ministero dell'Università e della Ricerca AIM (AIM1859703)Ministero dell'Università e della Ricerca Bando di Ateneo per il finanziamento di progetti di ricerca fondamentale ed applicata dedicato ai giovani Ricercatori: IDEAMinistero dell'Università e della Ricerca care sectors (Directorial Decree n. 931 of 06-06-2022) - project n. PNC0000003 - AdvaNced Technologies for Human-centrEd Medicine (project acronym: ANTHEM).Ministero dell'Università e della Ricerca cod:CN000000041. Bando giovani ricercatori D.R. n.834 del 30/09/2022 Università Vanvitelli project: MirandaMinistero dell'Università e della Ricerca converted by law n. 101 of 2021) in the call for the funding of research initiatives for technologiesMinistero dell'Università e della Ricerca CUP: J97G22000400006Ministero dell'Università e della Ricerca Drugs Based on RNA TechnologyMinistero dell'Università e della Ricerca established with the decree-law 6 May 2021Ministero dell'Università e della Ricerca innovative trajectories in the healthMinistero dell'Università e della Ricerca MUR-PRIN 2022A93K7SMinistero dell'Università e della Ricerca MUR-PRIN/PNRR2022:P20225KJ5LMinistero dell'Università e della Ricerca n. 59Ministero dell'Università e della Ricerca National Centre for Gene TherapyMinistero dell'Università e della Ricerca National Plan for NRRP Complementary Investments (PNCMinistero dell'Università e della Ricerca PNRR-CN3Ministero dell'Università e della Ricerca PON Ricerca e Innovazione 2014-2020 Linea 1Ministero dell'Università e della Ricerca PRIN P2022F3YRFMinistero dell'Università e della Ricerca PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE - Bando 2022 PNRR Prot. P2022KMP9KMinistero dell'Università e della Ricerca PrognosticMinistero dell'Università e della Ricerca Project: D3-4 Health - Digital Driver DiagnosticsMinistero dell'Università e della Ricerca Project PIR01_00032 BIO OPEN LAB BOL "CUP" J37E19000050007Ministero dell'Università e della Ricerca Project "Rafforzamento e creazione di IR nell'ambito del Piano Nazionale di Ripresa e Resilienza (PNRR)"- Prot IR0000028 "PRP@CERIC"Ministero dell'Università e della Ricerca Therapeutics for sustainable Health care - PNC0000001 CUP: B53C22006090001.Università degli Studi della Campania Luigi Vanvitelli EPI- MET Fondo Crescita Sostenibile - Accordi per l'Innovazione di cui al D.M. 31.12.2021 e D.D. 18.03.2022 Progetto posizione n. 34Università degli Studi della Campania Luigi Vanvitelli n. progetto F/310034/03/X56
6 · The paper itself

Abstract

backgroundBreast cancer manifests as a heterogeneous pathology marked by complex metabolic reprogramming essential to satisfy its energy demands. Oncogenic signals boost the metabolism, modifying fatty acid synthesis and glucose use from the onset to progression and therapy resistant-forms. However, the exact contribution of metabolic dependencies during tumor evolution remains unclear.

methodsIn this study, we elucidate the connection between FASN and LDHA, pivotal metabolic genes, and their correlation with tumor grade and therapy response using datasets from public repositories. Subsequently, we evaluated the metabolic and proliferative functions upon FASN and LDHA inhibition in breast cancer models. Lastly, we integrated metabolomic and lipidomic analysis to define the contributions of metabolites, lipids, and precursors to the metabolic phenotypes.

resultsCollectively, our findings indicate metabolic shifts during breast cancer progression, unvealling two distinct functional energy phenotypes associated with aggressiveness and therapy response. Specifically, FASN exhibits reduced expression in advance-grade tumors and therapy-resistant forms, whereas LDHA demonstrates higher expression. Additionally, the biological and metabolic impact of blocking the enzymatic activity of FASN and LDHA was correlated with resistant conditions.

conclusionsThese observations emphasize the intrinsic metabolic heterogeneity within breast cancer, thereby highlighting the relevance of metabolic interventions in the field of precision medicine.

Indexed as

Breast NeoplasmsFatty Acid Synthase, Type ICell Line, TumorCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansLipidomicsL-Lactate DehydrogenaseMetabolomicsFASN protein, humanFatty Acid Synthase, Type ILDHA protein, humanL-Lactate DehydrogenaseBreast cancerFASNLDHAMetabolismTamoxifen resistance

Identifiers

PMID39044184
PMCPMC11267768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.